Cartesian Therapeutics has announced updated efficacy and safety data from the Phase IIb trial of its mRNA cell therapy candidate for generalised myasthenia gravis (MG), Descartes-08. The results ...
GAITHERSBURG, Md., July 02, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering mRNA cell therapy for ...
GAITHERSBURG, Md., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a clinical-stage biotechnology company pioneering mRNA cell ...
FREDERICK, Md., May 30, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (“Cartesian” or the “Company”), a clinical-stage biotechnology company pioneering cell therapy for ...
On Wednesday, H.C. Wainwright adjusted its outlook on Cartesian Therapeutics (NASDAQ: RNAC), boosting the biotech company's price target from $41.00 to $45.00 while sustaining a Buy rating on the ...
Cartesian Therapeutics, Inc. has announced the enrollment of the first participant in its Phase 3 AURORA trial for Descartes-08, its lead cell therapy candidate aimed at treating myasthenia gravis (MG ...
(MENAFN- GlobeNewsWire - Nasdaq) 100% LLDAS response rate observed in patients with SLE who received Descartes-08 in Phase 2 open-label trial reaching Month 3 follow-up (n=3) Disease remission ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback